News & Updates

Adding the anti-PD-1 monoclonal antibody tislelizumab to chemotherapy in the first-line treatment of PD-1-positive advanced gastric or gastroesophageal junction adenocarcinoma appears to produce significant and clinically meaningful improvements in survival outcomes while having an acceptable safety profile, according to interim data from the phase III RATIONALE 305 trial.

Treatment with single fraction radiation therapy (RT) results in lesser hepatic pain in most patients with end-stage hepatocellular carcinoma (HCC) or liver metastases, according to a study presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).

Increased consumption of plant-based foods is associated with a lower risk of developing colorectal cancer (CRC) in men, according to the Multiethnic Cohort study.

Giving chemotherapy to patients with synchronous and unresectable liver metastases from colorectal cancer before undergoing primary tumour resection helps boost survival outcomes, according to a phase III trial presented at this year’s ASCO Gastrointestinal Cancer Symposium (ASCO GI).

Tumour response-speed heterogeneity to first-line chemotherapy is predictive of early disease progression and shorter survival in patients with metastatic colorectal cancer, reveals a study.

In men with localized prostate cancer undergoing radical prostatectomy and treated with 5α-reductase inhibitor (5-ARI), preoperative levels of circulating 11-oxygenated androgens can indicate either disease progression or improved survival, a recent study has found.

Patients on oral chemotherapy, who underwent a pharmacist-led hypertension management program, show improvements in blood pressure (BP) control as well as lower mean BP readings over time, reports a recent study.